Novo Nordisk's Wegovy Sales Growth Stalls in U.S. Amid Competition, Reimbursement Hurdles -- Market Talk

Dow Jones

Mar 27, 2025

1344 GMT - Novo Nordisk sees flat U.S. weekly prescription rate growth for its obesity treatment Wegovy due to competition from U.S. rival Eli Lilly and compounding pharmacies, coupled with reimbursement challenges, Morgan Stanley analysts say. The Danish pharmaceutical company could trim its sales guidance, possibly alongside its 1Q results, due to the slower U.S. prescription growth, they say. While long-term forecasts still indicate potential upside, the future of the obesity market, peak sales potential and longevity of Novo Nordisk's weight loss drug portfolio remain uncertain, they add. The analysts also cite Eli Lilly's market share gains in the U.S. and product differentiation, including greater weight loss and better tolerability. (helena.smolak@wsj.com)

(END) Dow Jones Newswires

March 27, 2025 09:45 ET (13:45 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2522340301"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2522340301\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2522340301?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-03-27 21:45","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2522340301","market":"other","top_or_hot":-1,"title":"Novo Nordisk's Wegovy Sales Growth Stalls in U.S. Amid Competition, Reimbursement Hurdles -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1344 GMT - Novo Nordisk sees flat U.S. weekly prescription rate growth for its obesity treatment Wegovy due to competition from U.S. rival Eli Lilly and compounding pharmacies, coupled with reimbursement challenges, Morgan Stanley analysts say. The Danish pharmaceutical company could trim its sales guidance, possibly alongside its 1Q results, due to the slower U.S. prescription growth, they say. While long-term forecasts still indicate potential upside, the future of the obesity market, peak sales potential and longevity of Novo Nordisk's weight loss drug portfolio remain uncertain, they add. The analysts also cite Eli Lilly's market share gains in the U.S. and product differentiation, including greater weight loss and better tolerability. (helena.smolak@wsj.com) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 27, 2025 09:45 ET (13:45 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novo Nordisk's Wegovy Sales Growth Stalls in U.S. Amid Competition, Reimbursement Hurdles -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovo Nordisk's Wegovy Sales Growth Stalls in U.S. Amid Competition, Reimbursement Hurdles -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-03-27 21:45</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1344 GMT - Novo Nordisk sees flat U.S. weekly prescription rate growth for its obesity treatment Wegovy due to competition from U.S. rival Eli Lilly and compounding pharmacies, coupled with reimbursement challenges, Morgan Stanley analysts say. The Danish pharmaceutical company could trim its sales guidance, possibly alongside its 1Q results, due to the slower U.S. prescription growth, they say. While long-term forecasts still indicate potential upside, the future of the obesity market, peak sales potential and longevity of Novo Nordisk's weight loss drug portfolio remain uncertain, they add. The analysts also cite Eli Lilly's market share gains in the U.S. and product differentiation, including greater weight loss and better tolerability. (helena.smolak@wsj.com) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 27, 2025 09:45 ET (13:45 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NVO","symbol_name":"诺和诺德","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2522340301","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2522340301","pubTimestamp":1743083100,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"1344 GMT - Novo Nordisk sees flat U.S. weekly prescription rate growth for its obesity treatment Wegovy due to competition from U.S. rival Eli Lilly and compounding pharmacies, coupled with reimbursement challenges, Morgan Stanley analysts say. The Danish pharmaceutical company could trim its sales guidance, possibly alongside its 1Q results, due to the slower U.S. prescription growth, they say. While long-term forecasts still indicate potential upside, the future of the obesity market, peak sales potential and longevity of Novo Nordisk's weight loss drug portfolio remain uncertain, they add. The analysts also cite Eli Lilly's market share gains in the U.S. and product differentiation, including greater weight loss and better tolerability. ","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"NVO":"诺和诺德"},"translate_title":"由于竞争和报销障碍，诺和诺德的Wegovy在美国的销售增长陷入停滞——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVO":1},"content_text":"1344 GMT - Novo Nordisk sees flat U.S. weekly prescription rate growth for its obesity treatment Wegovy due to competition from U.S. rival Eli Lilly and compounding pharmacies, coupled with reimbursement challenges, Morgan Stanley analysts say. The Danish pharmaceutical company could trim its sales guidance, possibly alongside its 1Q results, due to the slower U.S. prescription growth, they say. While long-term forecasts still indicate potential upside, the future of the obesity market, peak sales potential and longevity of Novo Nordisk's weight loss drug portfolio remain uncertain, they add. The analysts also cite Eli Lilly's market share gains in the U.S. and product differentiation, including greater weight loss and better tolerability. (helena.smolak@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 27, 2025 09:45 ET (13:45 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}